Evidence review

Beta-Alanine And The Brain: A Ten-Person Trial

The most interesting cognition paper on this shelf analysed six supplemented participants and four controls. It is worth reading, it is worth being careful about, and it is the clearest example anywhere in this category of how a small finding becomes a large claim.

By Mind Honey Pro Team · Last updated October 29, 2026 · 9 min read · Evidence review · Reviewed by Dr. Mary Cunningham

What beta-alanine is

Beta-alanine is an amino acid, and unlike most of the ones on a supplement shelf it is not used to build protein. Its job is to combine with histidine to make carnosine, and it is the rate-limiting half of that reaction, which is why supplementing it raises carnosine where supplementing histidine does not.

Carnosine accumulates in muscle and in brain tissue over weeks rather than hours. That timescale is the single most important fact about this compound: nothing about it is an acute effect, and every study that found anything ran for a month or more.

Why it reaches a cognition label at all

Almost all of the beta-alanine literature is about exercise. It arrives on a memory label through carnosine's presence in brain tissue and through a small, recent set of papers asking whether raising it there does anything measurable. That set is the subject of this article.

The ten-person imaging trial

The trial in question gave 2.4 g of beta-alanine a day for ten weeks to men and women aged 60 to 80 and reported improved fractional anisotropy scores in the hippocampus and amygdala. Fractional anisotropy is a diffusion imaging measure related to white matter structure.

Six supplemented participants and four controls were analysed. That is ten people, and the number is in the paper rather than hidden in it. A result in ten people is a reason to run a larger study, and it is the beginning of a literature rather than a conclusion.

It is also not a memory score. The trial reported an imaging change, and the step from a white-matter measure to a person noticing something about their own recall is a step the trial did not take.

• The dose was 2.4 g a day, which is sixty times a typical multi-ingredient label row.
• The duration was ten weeks, which is longer than most buyers give any capsule.
• The population was 60 to 80 years old, which is the population these products are sold to.
• The outcome was an imaging measure rather than a cognitive test score.
• The analysed sample was ten people.

What sits around it

Five entries, read from their own abstracts. Two are reviews, one is a meta-analysis that found nothing, and the most interesting one analysed ten people.

The meta-analysis of histidine-containing dipeptides is the strongest thing in that table, and it is careful about itself: it found an improvement in delayed recall and closed by asking for the doses to be standardised. An author asking for standardisation is an author telling you the literature is not settled.

The NEAT trial approached the same question from the other end, giving 2 g of carnosine itself daily for up to twelve weeks and reporting better cognitive outcomes among its younger participants. Supplying the finished dipeptide rather than its precursor is a different experiment, and it is a useful cross-check.

Why the precursor rather than the dipeptide

Carnosine taken by mouth is broken apart in the blood before much of it reaches tissue, which is the practical reason supplement research gravitated to beta-alanine in the first place. Supplying the rate-limiting building block lets the body assemble the dipeptide where it is wanted rather than delivering it whole and losing most of it on the way.

That detour has a cost in time. Tissue carnosine rises over weeks of daily dosing rather than hours, which is why every protocol in the table above runs for four weeks at minimum, and why an acute dose of this compound has nothing to show for itself.

The finding that points the other way

A literature summary that only collects positive results is an advertisement. A 2026 systematic review and multilevel meta-analysis looked at repeated sprint ability, which is the outcome beta-alanine is best known for, and found no ergogenic effect.

That matters here for a specific reason. If the compound's flagship performance claim does not survive a modern pooled analysis, a reader is entitled to be cautious about a much newer, much smaller cognitive literature standing on the same compound.

It cuts both ways, of course. A null result on sprinting says nothing directly about white matter. What it does is set the temperature: this is a compound whose effects are subtle enough to disappear in pooled data, not one whose effects are obvious.

The dose scale, end to end

A scale rather than a recommendation. Nothing here is advice to take a larger amount.

Read that table from the bottom up and the gap is the whole story. The International Society of Sports Nutrition position stand sets 4 to 6 g a day for four weeks as the working threshold for a measurable change, and a typical label row on a multi-ingredient capsule is under one per cent of that.

This is not an argument that a small row is worthless in some cosmic sense. It is the observation that nobody has published a human result at that amount, so there is nothing to point at.

The tingling, and where it applies

Beta-alanine has one famous effect and it is not a benefit. Paraesthesia, the tingling sensation across the face, neck and hands, is the reason the compound is sold in sustained-release forms and split doses.

A systematic risk assessment and meta-analysis describes it as the only consistently reported effect and ties it to single doses of roughly 800 mg and above. The position stand reaches the same conclusion from the performance side.

Which means the warning does not transfer to a milligram row. A label carrying tens of milligrams sits an order of magnitude below the threshold, and repeating a tingling warning at that amount would be borrowing a caution from a dose the product does not contain.

How to hold all of this at once

1. The compound is real, its mechanism is plausible and its timescale is weeks.
2. The cognition literature is three papers, one of which analysed ten people.
3. Every positive finding used grams. The lowest was 2.4 g a day for ten weeks.
4. A recent pooled analysis of its best-known outcome found nothing.
5. The tingling warning belongs to doses in the hundreds of milligrams and up.
6. A milligram row on a multi-ingredient panel has no published human result behind it, and saying so is more useful than either enthusiasm or contempt.

References